Which has higher valuation and earnings, ENLV or LNAI?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A

Is ENLV or LNAI more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A 248.08% 206.39% Lunai Bioworks N/A -1,243.45% -1,617.76%

Do analysts prefer GNTA or LNAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, GNTA or LNAI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A

Is GNTA or LNAI more profitable?

Genenta Science's return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A Lunai Bioworks N/A -1,243.45% -1,617.76%

Do analysts prefer LTRN or LNAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, LTRN or LNAI?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.45 N/A Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A

Is LTRN or LNAI more profitable?

Lantern Pharma's return on equity of -198.34% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -198.34% -129.08% Lunai Bioworks N/A -1,243.45% -1,617.76%

Does the media favor LTRN or LNAI?

In the previous week, Lantern Pharma and Lantern Pharma both had 3 articles in the media. Lantern Pharma's average media sentiment score of 0.33 beat Lunai Bioworks' score of 0.00 indicating that Lantern Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lunai Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend LNAI or ESLA?

Estrella Immunopharma has a consensus price target of $8.00, suggesting a potential upside of 932.26%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Estrella Immunopharma is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, LNAI or ESLA?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A

Is LNAI or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Estrella Immunopharma N/A N/A -397.36%

Do analysts rate LNAI or SGMO?

Sangamo Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75

Does the media favor LNAI or SGMO?

In the previous week, Lunai Bioworks had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for Lunai Bioworks and 1 mentions for Sangamo Therapeutics. Lunai Bioworks' average media sentiment score of 0.00 equaled Sangamo Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lunai Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lunai Bioworks (LNAI) Competitors

$2.43 -0.05 (-1.98%)

As of 09:44 AM Eastern

Compare

LNAI vs. ENLV, GNTA, LTRN, ESLA, and SGMO

Should you buy Lunai Bioworks stock or one of its competitors? MarketBeat compares Lunai Bioworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lunai Bioworks include Enlivex Therapeutics (ENLV), Genenta Science (GNTA), Lantern Pharma (LTRN), Estrella Immunopharma (ESLA), and Sangamo Therapeutics (SGMO). These companies are all part of the "biotechnology" industry.

How does Lunai Bioworks compare to Enlivex Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Lunai Bioworks is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Enlivex Therapeutics' return on equity of 248.08% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

Enlivex Therapeutics presently has a consensus price target of $247.50, suggesting a potential upside of 11,547.06%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Enlivex Therapeutics is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Enlivex Therapeutics had 6 more articles in the media than Lunai Bioworks. MarketBeat recorded 9 mentions for Enlivex Therapeutics and 3 mentions for Lunai Bioworks. Enlivex Therapeutics' average media sentiment score of 0.70 beat Lunai Bioworks' score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Enlivex Therapeutics	Positive
Lunai Bioworks	Neutral

Enlivex Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

Summary

Enlivex Therapeutics beats Lunai Bioworks on 12 of the 14 factors compared between the two stocks.

How does Lunai Bioworks compare to Genenta Science?

Genenta Science (NASDAQ:GNTA) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Genenta Science's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

In the previous week, Lunai Bioworks had 3 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for Lunai Bioworks and 0 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.00 equaled Lunai Bioworks'average media sentiment score.

Company	Overall Sentiment
Genenta Science	Neutral
Lunai Bioworks	Neutral

Genenta Science has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

Summary

Genenta Science beats Lunai Bioworks on 5 of the 7 factors compared between the two stocks.

How does Lunai Bioworks compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by insiders. Comparatively, 0.5% of Lunai Bioworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lantern Pharma has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

Lantern Pharma's return on equity of -198.34% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-198.34%	-129.08%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

In the previous week, Lantern Pharma and Lantern Pharma both had 3 articles in the media. Lantern Pharma's average media sentiment score of 0.33 beat Lunai Bioworks' score of 0.00 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lunai Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lunai Bioworks is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

Summary

Lantern Pharma beats Lunai Bioworks on 7 of the 9 factors compared between the two stocks.

How does Lunai Bioworks compare to Estrella Immunopharma?

Lunai Bioworks (NASDAQ:LNAI) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Estrella Immunopharma has a consensus price target of $8.00, suggesting a potential upside of 932.26%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Estrella Immunopharma is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lunai Bioworks is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Lunai Bioworks had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for Lunai Bioworks and 0 mentions for Estrella Immunopharma. Lunai Bioworks' average media sentiment score of 0.00 equaled Estrella Immunopharma'saverage media sentiment score.

Company	Overall Sentiment
Lunai Bioworks	Neutral
Estrella Immunopharma	Neutral

Estrella Immunopharma's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Estrella Immunopharma	N/A	N/A	-397.36%

Lunai Bioworks has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

Summary

Estrella Immunopharma beats Lunai Bioworks on 10 of the 12 factors compared between the two stocks.

How does Lunai Bioworks compare to Sangamo Therapeutics?

Lunai Bioworks (NASDAQ:LNAI) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Sangamo Therapeutics has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

Lunai Bioworks has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

In the previous week, Lunai Bioworks had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for Lunai Bioworks and 1 mentions for Sangamo Therapeutics. Lunai Bioworks' average media sentiment score of 0.00 equaled Sangamo Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lunai Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lunai Bioworks has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Lunai Bioworks' return on equity of -1,243.45% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Sangamo Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Sangamo Therapeutics beats Lunai Bioworks on 10 of the 14 factors compared between the two stocks.

Get Lunai Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNAI vs. The Competition

Export

Metric	Lunai Bioworks	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.01M	$3.58B	$6.86B	$12.99B
Dividend Yield	N/A	3.77%	2.60%	9.78%
P/E Ratio	-6.08	7.68	280.40	25.25
Price / Sales	N/A	1,178.80	558.43	76.37
Price / Cash	N/A	103.01	71.79	50.79
Price / Book	-0.25	17.08	12.95	6.09
Net Income	-$178.01M	-$12.52M	$3.49B	$347.95M
7 Day Performance	20.35%	2.34%	2.42%	3.08%
1 Month Performance	-21.33%	-5.12%	-2.86%	-3.01%
1 Year Performance	N/A	52.13%	75.31%	20.49%

Lunai Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNAI Lunai Bioworks	0.5406 of 5 stars	$2.43 -2.0%	N/A	N/A	$11.01M	N/A	N/A	20	News Coverage
ENLV Enlivex Therapeutics	3.9235 of 5 stars	$2.09 +7.2%	$247.50 +11,742.1%	-89.5%	$35.18M	N/A	N/A	70	Analyst Revision
GNTA Genenta Science	0.6253 of 5 stars	$1.49 -1.3%	N/A	-64.8%	$35.15M	N/A	N/A	7	Gap Up
LTRN Lantern Pharma	0.7148 of 5 stars	$2.63 -0.8%	N/A	-46.2%	$33.56M	N/A	N/A	20	Upcoming Earnings
ESLA Estrella Immunopharma	2.1232 of 5 stars	$0.71 -0.9%	$8.00 +1,020.9%	-14.1%	$30.71M	N/A	N/A	N/A	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNAI) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lunai Bioworks (LNAI) Competitors

LNAI vs. ENLV, GNTA, LTRN, ESLA, and SGMO

How does Lunai Bioworks compare to Enlivex Therapeutics?

Summary

How does Lunai Bioworks compare to Genenta Science?

Summary

How does Lunai Bioworks compare to Lantern Pharma?

Summary

How does Lunai Bioworks compare to Estrella Immunopharma?

Summary

How does Lunai Bioworks compare to Sangamo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lunai Bioworks (LNAI) Competitors

LNAI vs. ENLV, GNTA, LTRN, ESLA, and SGMO

How does Lunai Bioworks compare to Enlivex Therapeutics?

Which has higher valuation and earnings, ENLV or LNAI?

Do institutionals & insiders have more ownership in ENLV or LNAI?

Is ENLV or LNAI more profitable?

Do analysts prefer ENLV or LNAI?

Does the media prefer ENLV or LNAI?

Which has more risk & volatility, ENLV or LNAI?

Summary

How does Lunai Bioworks compare to Genenta Science?

Do analysts prefer GNTA or LNAI?

Do insiders & institutionals have more ownership in GNTA or LNAI?

Is GNTA or LNAI more profitable?

Does the media prefer GNTA or LNAI?

Which has more risk and volatility, GNTA or LNAI?

Which has preferable earnings & valuation, GNTA or LNAI?

Summary

How does Lunai Bioworks compare to Lantern Pharma?

Do analysts prefer LTRN or LNAI?

Do institutionals and insiders hold more shares of LTRN or LNAI?

Which has more volatility and risk, LTRN or LNAI?

Is LTRN or LNAI more profitable?

Does the media favor LTRN or LNAI?

Which has higher earnings and valuation, LTRN or LNAI?

Summary

How does Lunai Bioworks compare to Estrella Immunopharma?

Do analysts recommend LNAI or ESLA?

Which has stronger earnings and valuation, LNAI or ESLA?

Do institutionals and insiders hold more shares of LNAI or ESLA?

Does the media favor LNAI or ESLA?

Is LNAI or ESLA more profitable?

Which has more volatility and risk, LNAI or ESLA?

Summary

How does Lunai Bioworks compare to Sangamo Therapeutics?

Which has stronger earnings & valuation, LNAI or SGMO?

Which has more volatility and risk, LNAI or SGMO?

Does the media favor LNAI or SGMO?

Is LNAI or SGMO more profitable?

Do analysts rate LNAI or SGMO?

Do insiders and institutionals have more ownership in LNAI or SGMO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools